UK Charity Starts Early-Stage Clinical Studies Of Lilly's Cdc7 Inhibitor
The drug development arm of the UK charity, Cancer Research UK, has started early clinical development of potentially a new type of anticancer, a Cdc7 inhibitor, discovered by Eli Lilly, in an effort that could boost traction in this new area of research.
You may also be interested in...
Sierra Oncology president and CEO Dr Nick Glover tells Mike Ward how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused of DNA damage repair (DDR) and $100m in the bank.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.